NDA 216016 · Bracco
Iomervu
Iomeprol · Intra-Arterial · Radiographic Contrast Agent
NovelLast checked: Nov 19, 2026Latest source record: Nov 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Nov 27, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. IOMERVU is for intra-arterial or intravenous use only [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. IOMERVU is for intra-arterial or intravenous use only. (2.1, 5.1)
What it is approved for
From the label in effect Feb 5, 2026.
IOMERVU is a radiographic contrast agent indicated for: Intra-arterial Procedures † ( 1.1 ) Cerebral arteriography, includingintra-arterial digital subtraction angiography (IA-DSA), in adults and pediatric patients Visceral and peripheral arteriography and aortography, including IA-DSA, in adults and pediatric patients Coronary arteriography and cardiac ventriculography in adults Radiographic evaluation of cardiac chambers and related arteries in pediatric patients Intravenous Procedures † ( 1.2 ) Computed tomography (CT) of the head and body in adults and pediatric patients CT angiography of intracranial, visceral, and lower extremity arteries in adults and pediatric patients Coronary CT angiography in adults and pediatric patients CT urography in adults and pediatric patients † Specific concentrations are recommended for each type of imaging procedure. ( 2.2 , 2.3 , 2.4 , 2.5 ) 1.1 Intra-arterial Procedures † IOMERVU is indicated for: Cerebral arteriography, including intra-arterial digital subtraction angiography (IA-DSA), in adults and pediatric patients Visceral and peripheral arteriography and aortography, including IA-DSA, in adults and pediatric patients Coronary arteriography and cardiac ventriculography in adults Radiographic evaluation of cardiac chambers and related arteries in pediatric patients 1.2 Intravenous Procedures † IOMERVU is indicated for: Computed tomography (CT) of the head and body in adults and pediatric patients CT angiography of intracranial, visceral, and lower extremity arteries in adults and pediatric patients Coronary CT angiography in adults and pediatric patients CT urography in adults and pediatric patients † Specific concentrations of IOMERVU are recommended for each type of imaging procedure [see Dosage and Administration ( 2.2 ,...
Mechanism: Iomeprol is a radiographic iodinated contrast agent that opacifies the vessels and body structures where the contrast agent is present following intravenous or intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of X-ray photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, the contrast agent does not diffuse into the extravascular space and contrast enhancement is generally due to the presence of contrast within the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
13 products under this application
- IOMERVU · IOMEPROL 52.5GM IODINE/150ML (350MG IODINE/ML · SOLUTION, INTRA-ARTERIAL · Discontinued
- IOMERVU · IOMEPROL 17.5GM IODINE/50ML (350MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
- IOMERVU · IOMEPROL 60GM IODINE/150ML (400MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
- IOMERVU · IOMEPROL 45GM IODINE/150ML (300MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
- IOMERVU · IOMEPROL 20GM IODINE/50ML (400MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
- IOMERVU · IOMEPROL 15GM IODINE/50ML (300MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
- IOMERVU · IOMEPROL 70GM IODINE/200ML (350MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Prescription
- IOMERVU · IOMEPROL 35GM IODINE/100ML (350MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Prescription
- IOMERVU · IOMEPROL 80GM IODINE/200ML (400MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Prescription
- IOMERVU · IOMEPROL 60GM IODINE/200ML (300MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
- IOMERVU · IOMEPROL 40GM IODINE/100ML (400MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Prescription
- IOMERVU · IOMEPROL 30GM IODINE/100ML (300MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
- IOMERVU · IOMEPROL 25GM IODINE/100ML (250MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Iomeprol" as an intervention, any sponsor and status, largest first.
- Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT AngiographyPivotal-lookingCompleted
GuerbetIndustry
NCT01255722 · 468 participants · Start Nov 2010 · Primary completion Sep 2012
Drug: iobitridol; iopromide and 1 more · For: Coronary Artery Disease
Sites: Angers, France; Brest, France; Le Plessis-Robinson, France · 23 sites in all
- Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT ExaminationsPivotal-lookingRecruiting
University Hospital AugsburgAcademic, hospital or other
NCT06965790 · 400 participants (planned) · Start Apr 1, 2025 · Primary completion Mar 2026
Drug: contrast media (Imeron 350, active ingredient Iomeprol) volume according to sex-specific blood volume · For: CT Scans; Contrast Media; Gender and 1 more
Sites: Augsburg, Germany
- Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)Pivotal-lookingCompleted
Deutsches Herzzentrum MuenchenAcademic, hospital or other
NCT00390585 · 324 participants · Start Jul 2006 · Primary completion Jan 2008
Drug: Iodixanol 320; Iomeprol 350 · For: Renal Insufficiency, Chronic; Angioplasty, Transluminal, Percutaneous Coronary; Coronary Arteriosclerosis
Sites: Munich, Germany; München, Germany
Philippe GauthierAcademic, hospital or other
NCT06062134 · 10 participants · Start Oct 18, 2023 · Primary completion Dec 21, 2023
Drug: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast · For: Post Operative Pain; Mechanisms of Analgesia
Sites: Brussels, Belgium
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Feasibility study of 'Triple-Low' technique for coronary artery computed tomography angiography (CCTA).
Wang S, Sun Z, Zeng Y, et al. · Sci Rep 2024 · Randomized Controlled Trial
- Effect of iomeprol on renal function immediately after abdominal angiography.
Murakami R, Tajima H, Kumazaki T · Acta Radiol 1996 · Clinical Trial, Randomized Controlled Trial
- Iomeprol vs iopamidol in intraarterial peripheral digital subtraction angiography.
Dacoronias D, Minguzzi P, Ugolotti U, et al. · Angiology 1992 · Clinical Trial, Comparative Study
- Incidence of contrast-induced nephropathy with volume supplementation--insights from a large cohort.
Mueller-Lenke N, Buerkle G, Klima T, et al. · Med Princ Pract 2008 · Clinical Trial, Research Support, Non-U.S. Gov't
- Iomeprol versus iopromide for intravenous urography.
de Geeter P, Melchior H · Br J Radiol 1994 · Clinical Trial, Clinical Trial, Phase III
- Incidence and severity of nonionic low-osmolar iodinated contrast medium-related adverse drug reactions in the Republic of Korea: Comparison by generic.
Jang EB, Suh CH, Kim PH, et al. · Medicine (Baltimore) 2023 · Meta-Analysis, Systematic Review
Sponsor: Bracco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.